ESR1 and breast cancer: Here, we focus on circumventing palbociclib resistance by targeting estrogen-receptor-positive (ER+) and estrogen-receptor-negative (ER−) breast cancers with a unique ribonucleotide reductase subtype M2 (RRM2) enzyme inhibitor.